EVO

Business Context and Reporting Period

This Form 6-K, filed on July 3, 2008, furnishes Evotec SE's (Evotec AG) Annual Report for the fiscal year ended December 31, 2007. The filing details the company's strategic transformation from a broad research services provider to a focused developer of novel pharmaceuticals, primarily targeting Central Nervous System (CNS) diseases, pain, and inflammation. Key strategic milestones in 2007 included the divestiture of non-core assets (Evotec Technologies and Chemical Development Business) and the agreement to acquire Renovis, Inc., which closed in May 2008.

Key Financial Metrics (2007)

Note: Financial figures for Continuing Operations exclude contributions from divested businesses (Evotec Technologies and Chemical Development Business). Operating result is presented before amortization and impairment.

Material Changes vs. Prior Period

• Revenue Decline: Revenues from continuing operations decreased by 19% to €32.9 million. This was driven by the divestiture of the Chemical Development Business (which accounted for 39.5% of 2007 total revenue prior to sale), delays in milestone payments, and the transfer of the library business to a joint venture.
• Increased Losses: The net loss widened to €48.1 million from €29.0 million. This was primarily due to a 22% increase in R&D expenditures to advance proprietary pipeline programs, lower gross profit from the shift away from fee-for-service models, and an impairment charge related to the Oxford Asymmetry International acquisition.
• Strategic Divestitures: Evotec sold its 89% interest in Evotec Technologies to PerkinElmer for €23.9 million and its Chemical Development Business to Aptuit for approximately €42.5 million (net purchase price).
• Acquisition of Renovis: The company completed a stock-for-stock acquisition of Renovis, Inc. in May 2008, adding a US footprint, late-stage preclinical assets, and approximately $79.4 million in cash and investments (as of Dec 31, 2007).

Guidance, Outlook, and Management Commentary

Liquidity and Runway: Management states that the pro-forma year-end cash position of €141 million, combined with anticipated collaboration payments, is sufficient to fund operating requirements through 2010.

Pipeline Progress:

• EVT 201 (Insomnia): Phase II proof-of-concept established. Management is actively seeking a partner for Phase III development and commercialization.
• EVT 302 (Smoking Cessation): Phase II trials commenced in February 2008. Data readouts expected in late 2008 and early 2009.
• EVT 101 (Pain/Alzheimer's): Phase I completed; Phase II expected to start in 2008.
• Renovis Pipeline: Two advanced preclinical programs (VR1 antagonist and P2X7 antagonist) are expected to enter clinical trials in 2008.

Market Outlook: The company expects to have six compounds in clinical development by the end of 2009, with three expected to have proof-of-concept data to attract partners. The NASDAQ listing of American Depositary Shares (ADS) is expected to enhance access to US capital markets.

Risks: Forward-looking statements are subject to risks including the failure to successfully integrate Renovis, unexpected merger costs, disruption to customer relationships, and the inherent risks of drug development (clinical trial failures).

Investor Verification Checklist

• Merger Integration: Verify the actual closing terms and financial impact of the Renovis acquisition completed in May 2008.
• Partnership Status: Confirm progress on securing a partner for EVT 201 (insomnia) and the status of the Pfizer collaboration regarding VR1 antagonists.
• Cash Burn Rate: Monitor quarterly cash flow to ensure the €141 million pro-forma liquidity is sufficient to fund operations through 2010 without dilutive capital raises.
• Clinical Data Readouts: Track the results of Phase II trials for EVT 302 (smoking cessation) and the initiation of Phase II for EVT 101.
• Revenue Mix: Assess the transition from fee-for-service revenue to milestone and royalty-based revenue streams.